Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Zenith Epigenetics Announces Publication of Covalent Bromodomain Inhibitors, Offering a Novel Approach to Targeting BET Bromodomains

No such message found

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Zenith Epigenetics Announces Publication of Covalent Bromodomain Inhibitors, Offering a Novel Approach to Targeting BET Bromodomains

BearDownAZ

Oct 01, 2018 09:43AM

Re: Zenith Epigenetics Announces Publication of Covalent Bromodomain Inhibitors, Offering a Novel Approach to Targeting BET Bromodomains

BearDownAZ

Oct 01, 2018 09:57AM

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics Announces Publication of Covalent Bromodomain Inhibitors, Offering a Novel Approach to Targeting BET Bromodomains

in response to

Zenith Epigenetics Announces Publication of Covalent Bromodomain Inhibitors, Offering a Novel Approach to Targeting BET Bromodomains

BearDownAZ

posted on Oct 02, 2018 10:27AM

And it made the cover of the Sept 27th issue of Journal of Medicinal Chemistry!

https://twitter.com/JMedChem/status/1046786772276060161

4 Recommendations

Reply New Message

Back To Forum List View

Please to post a reply